Latest news

Thumbnail image for EMA confirms risks of MS drug Zinbryta

EMA confirms risks of MS drug Zinbryta

The European Medicines Agency has concluded that the risks linked with use of Biogen and AbbVie's multiple sclerosis drug Zinbryta outweigh its benefits.

21st May 2018

Thumbnail image for Generic competition hits AZ’ first-quarter sales

Generic competition hits AZ’ first-quarter sales

AstraZeneca’s first-quarter performance has taken a hit from generic competition to Crestor, but the firm says the results are no surprise and that it will swing back into the black this year.

18th May 2018

Thumbnail image for NEJM publishes second successful Epidiolex trial in LGS

NEJM publishes second successful Epidiolex trial in LGS

The New England Journal of Medicine has published the second of two late stage studies showing that GW Pharma’s cannabinoid Epidiolex cut seizures in patients with the rare childhood epilepsy Lennox-Gastaut Syndrome.

17th May 2018

Thumbnail image for Dupixent trial hits targets in adolescent atopic dermatitis

Dupixent trial hits targets in adolescent atopic dermatitis

A late-stage study of Sanofi and Regeneron’s Dupixent in adolescents with atopic dermatitis has met its key targets, paving the way for a regulatory submission for drug targeting this younger patient group in the third quarter.

17th May 2018

Previous  --   9 10 11 12 13 14 15 16 17 18   --  Next

Latest jobs

View all

Download our apps

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.

Download